Panelists discuss how spinal muscular atrophy is an autosomal recessive genetic disease affecting motor neurons with 3 ...

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

"Spinal Muscular Atrophy Pipeline"Spinal Muscular Atrophy companies are Amniotics, Biohaven Pharmaceuticals, Hoffmann-La Roche, Amylon Therapeutics, Voyager Therapeutics, Catalyst Pharmaceuticals ...

Thiruvananthapuram: For the first time in India, pre-symptomatic treatment to an infant, diagnosed with spinal muscular atrophy (SMA) within days of birth, was provided in Kerala, marking a ...

Spinal muscular atrophy (SMA) is a severe motor neuron disease caused by mutations in the SMN1 gene, leading to reduced SMN protein levels. Although postnatal treatments like the antisense ...

The baby from Ranaghat in Nadia is suffering from spinal muscular atrophy (SMA) Type I, a condition that causes progressive weakening of the muscles and nerves A 16-month-old girl with a rare genetic ...

Roche’s Evrysdi (risdiplam) tablets have been approved by the European Commission (EC) to treat spinal muscular atrophy (SMA). The new, room-temperature stable formulation of Evrysdi may offer ...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety demonstrated in ...

BiogenBIIB said Wednesday its experimental treatment helped children with a devastating muscle-wasting disease even after they received an approved gene therapy from NovartisNVS.The company already ...

Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal muscular atrophy ...